Alina Jurcoane

Alina Jurcoane

Auto-generated profile, based on publicly available information

Alina Jurcoane

UK Bonn, Radiologie, Bonn

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in NeuroImage
Verified
Journal Article
Closed access
OGO.L. Gamboa
O.L. Gamboa
ETE. Tagliazucchi
E. Tagliazucchi
FWF. von Wegner
F. von Wegner
AJA. Jurcoane
A. Jurcoane
MWM. Wahl
M. Wahl
UZU. Ziemann
U. Ziemann

7 October 2014 in Neuroradiology
Verified
Journal Article
Closed access
PDF file
SLStephanie Lescher
Stephanie Lescher
AJAlina Jurcoane
Alina Jurcoane
AVAndreas Veit
Andreas Veit
OBOliver Bähr
Oliver Bähr
RDRalf Deichmann
Ralf Deichmann
EHElke Hattingen
Elke Hattingen

1 May 2010 in Neurosurgery
Verified
Journal Article
Closed access
PDF file
EHElke Hattingen
Elke Hattingen
AJAlina Jurcoane
Alina Jurcoane
JMJulia Melber
Julia Melber
SBStella Blasel
Stella Blasel
FZFriedhelm E. Zanella
Friedhelm E. Zanella
OSOliver C. Singer
Oliver C. Singer
OBJECTIVE. Diffusion tensor imaging (DTI) parameters were investigated in patients with chronic idiopathic hydrocephalus to evaluate microstructural cha

7 August 2013 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
EHElke Hattingen
Elke Hattingen
AJAlina Jurcoane
Alina Jurcoane
KDKeivan Daneshvar
Keivan Daneshvar
UPUlrich Pilatus
Ulrich Pilatus
MMMichel Mittelbronn
Michel Mittelbronn
OBOliver Bähr
Oliver Bähr
Background Anti-angiogenic treatment in recurrent glioblastoma patients suppresses contrast enhancement and reduces vasogenic edema while non-enhancing tumor progression is common. Thus, the importance of T2-weighted imaging is increasing. We therefore quantified T2 relaxation times, which are the basis for the image contrast on T2-weighted images. Methods Conventional and quantitative MRI procedures were performed on 18 patients with recurrent glioblastoma before treatment with bevacizumab and every 8 weeks thereafter until further tumor progression. We segmented the tumor on conventional MRI into 3 subvolumes: enhancing tumor, non-enhancing tumor, and edema. Using coregistered quantitative maps, we followed changes in T2 relaxation time in each subvolume. Moreover, we generated differential T2 maps by a voxelwise subtraction using the first T2 map under bevacizumab as reference. Results Visually segmented areas of tumor and edema did not differ in T2 relaxation times. Non-enhancing tumor volume did not decrease after commencement of bevacizumab treatment but strikingly increased at progression. Differential T2 maps clearly showed non-enhancing tumor progression in previously normal brain. T2 relaxation times decreased under bevacizumab without re-increasing at tumor progression. A decrease of <26 ms in the enhancing tumor following exposure to bevacizumab was associated with longer overall survival. Conclusions Combining quantitative MRI and tumor segmentation improves monitoring of glioblastoma patients under bevacizumab. The degree of change in T2 relaxation time under bevacizumab may be an early response parameter predictive of overall survival. The sustained decrease in T2 relaxation times toward values of healthy tissue masks progressive tumor on conventional T2-weighted images. Therefore, quantitative T2 relaxation times may detect non-enhancing progression better than conventional T2-weighted imaging.

1 February 2014 in Journal of Affective Disorders
Verified
Journal Article
Closed access
VOViola Oertel
Viola Oertel
BRBritta Reinke
Britta Reinke
GAGilberto Alves
Gilberto Alves
AJAlina Jurcoane
Alina Jurcoane
SWSofia Wenzler
Sofia Wenzler
CKChristian Knöchel
Christian Knöchel

1 October 2012 in NeuroImage
Verified
Journal Article
Closed access
SVSteffen Volz
Steffen Volz
UNUlrike Nöth
Ulrike Nöth
AJAlina Jurcoane
Alina Jurcoane
UZUlf Ziemann
Ulf Ziemann
EHElke Hattingen
Elke Hattingen
RDRalf Deichmann
Ralf Deichmann